Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial

Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial

Introduction Adoptive cell transfer of genetically engineered T cells is a promising treatment for malignancies; however, there are few ideal cancer antigens expressed on the cell surface, and the development of chimeric antigen receptor T cells (CAR-T cells) for solid tumour treatment has been slow...

Full description

Bibliographic Details
Main Authors: Hiroaki Ikeda, Hiroshi Shiku, Shigehisa Kitano, Koji Kato, Shinichi Kageyama, Yoshihiro Miyahara, Mikiya Ishihara, Kazuto Takesako, Takashi Watanabe, Akihiko Matsumine, Makoto Endo, Tomomi Yamada, Satoshi Okumura, Naomi Kiyota, Kimikazu Yakushijin, Kohichi Takada, Shinichiro Kobayashi, Yasuhiro Nagata, Taizo Shiraishi, Keizo Horibe, Hiroshi Miwa
Format: Article
Language:English
Published: BMJ Publishing Group 2022-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/11/e065109.full

Internet

https://bmjopen.bmj.com/content/12/11/e065109.full

Similar Items